Compare IMRX & GLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMRX | GLO |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.6M | 246.3M |
| IPO Year | 2021 | 2006 |
| Metric | IMRX | GLO |
|---|---|---|
| Price | $5.14 | $5.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.20 | N/A |
| AVG Volume (30 Days) | ★ 616.7K | 100.7K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.86 | $5.39 |
| 52 Week High | $10.08 | $6.18 |
| Indicator | IMRX | GLO |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 38.74 |
| Support Level | $4.82 | $5.74 |
| Resistance Level | $5.27 | $5.80 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 73.01 | 5.88 |
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.